The Chronic Injection Burden Driving Innovation in Neovascular Retinal Disease

Neovascular retinal diseases — including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO) — share a common biological driver: the persistent overexpression of VEGF (vascular endothelial growth factor), which fuels pathological choroidal neovascularization (CNV) beneath the retinal pigment epithelium. Current standard-of-care agents — ranibizumab, bevacizumab, and aflibercept — achieve visual stabilization in the majority of nAMD patients, but re-injection burden remains a fundamental barrier to durable outcomes in real-world settings.

The molecular architecture of the disease is well-established. VEGF-A is the dominant target, but VEGF-B and placental growth factor (PlGF) are co-targeted by fusion protein antagonists such as aflibercept. Choroidal neovascularization produces two primary anatomical endpoints tracked across clinical and patent evidence: subretinal fluid (SRF) and intraretinal fluid (IRF), both measurable by optical coherence tomography (OCT). The central subfoveal thickness (CST) — and critically, its fluctuation between dosing intervals — has emerged as a functional endpoint in its own right, with Adverum Biotechnologies filing a distinct patent covering reduction of CST fluctuation as a limitation of periodic IVT dosing.

This persistent treatment burden — not efficacy failure — is the primary driver of the innovation wave captured in patent filings from 2017 to 2026. The field is bifurcating: one track pursues gene therapy to eliminate injections entirely; the other pursues dose escalation and molecular engineering to extend the interval between injections. A third track explores entirely new delivery architectures — suprachoroidal space administration, biodegradable implants, and topical routes — that could transform the treatment experience without requiring gene therapy’s biological complexity.

AAV Gene Therapy: The Single-Dose Durability Case

AAV-mediated gene therapy represents the dominant innovation cluster in retrieved patent data, with the central mechanism being intravitreal or subretinal administration of recombinant adeno-associated virus (rAAV) particles engineered to transduce retinal cells and enable sustained in vivo expression of anti-VEGF proteins — eliminating the need for repeated injections. Two companies lead this cluster with distinct molecular strategies: Adverum Biotechnologies and RegenxBio.

Adverum Biotechnologies: Engineered Capsid + Aflibercept Transgene

Adverum Biotechnologies holds the densest patent family in the retrieved dataset, spanning more than ten jurisdictions — US, WO, EP, AU, JP, SG, IN, MX, BR, CA, and CN — with a continuous filing window from 2017 to 2026. The platform centres on an AAV2 capsid variant incorporating an engineered LGETTRP heptapeptide inserted between positions 587 and 588 of the AAV2 VP1 capsid protein. This modification is claimed to enhance retinal transduction efficiency upon intravitreal administration, distinct from natural AAV2 tropism which requires higher doses for equivalent retinal transduction. The transgene encodes a polypeptide with ≥95% sequence identity to aflibercept (SEQ ID NO: 35), flanked by AAV2 inverted terminal repeats (ITRs).

“A single low unit dose of 6×10¹¹ vg/eye stabilized visual acuity in all treated individuals, with none requiring rescue anti-VEGF IVT injections — and resolved IRF and SRF that had been refractory to prior long-term IVT injections of aflibercept, ranibizumab, or bevacizumab.”

The clinical signal embedded in Adverum’s filings is striking. Retrieved data indicate that the same 6×10¹¹ vg/eye dose unexpectedly resolved IRF and SRF that had been refractory to prior long-term IVT injections. Retinal fluid was reduced by approximately 80% relative to pre-treatment baseline in some arms. This refractory patient population — those whose retinal fluid does not resolve with conventional IVT therapy — represents a clinically validated gene therapy indication that may support accelerated regulatory pathways, as recognised by FDA guidance on unmet medical need designations.

A bridging protocol is also explicitly claimed in multiple Adverum filings: an anti-VEGF IVT injection is administered prior to the rAAV gene therapy dose, using short-acting pharmacological control to stabilize disease while viral transgene expression ramps up. This design reflects a practical clinical consideration for managing the gene therapy induction window.

RegenxBio: HuPTM Fab Glycosylation Engineering

RegenxBio pursues a distinct molecular strategy: delivery of fully human post-translationally modified (HuPTM) anti-VEGF monoclonal antibody Fab fragments (HuGlyFabVEGFi) via AAV vectors. The HuPTM concept specifically addresses immunogenicity concerns by ensuring α2,6-sialylation and absence of NeuGc and α-Gal xenoantigens — glycan engineering claimed to reduce immunogenicity compared to non-human glycosylation patterns. RegenxBio filings cover nAMD, DME, and DR indications and describe multiple administration routes: subretinal, suprachoroidal, intraretinal, and juxtascleral delivery. Johns Hopkins University appears as a co-assignee on at least two active filings in this family, reflecting an academic-industrial partnership model consistent with structures tracked by WIPO in its annual patent landscape reports.

Extended-Interval IVT Regimens: The Near-Term Commercial Competition

While gene therapy targets the elimination of injections, Bayer Healthcare and Novartis are pursuing durability improvements within the intravitreal injection paradigm — a strategy that avoids the complexity of viral vector biology and surgical delivery. The core approach is dose escalation combined with interval extension: increasing the molar dose of aflibercept from the approved 2 mg to 8 mg per IVT injection, then extending maintenance intervals to 12, 16, or 20 weeks.

Bayer’s pharmacokinetic rationale is explicitly stated in retrieved JP filings: free aflibercept clearance from the ocular compartment is approximately 0.37–0.46 mL/day, and the time to reach the lower limit of quantitation (LLOQ) in the ocular compartment after an 8 mg IVT dose is approximately 15 weeks. This 15-week ocular persistence directly supports the HDq16 and HDq20 extended-interval regimens. One EU patent application extends this logic further, describing maintenance intervals up to every 24 weeks (6 months). The loading phase consists of 3 monthly 8 mg doses, followed by maintenance dosing at the extended interval — a regimen structure that maps directly to what appears to be the high-dose aflibercept (EYLEA HD) product.

Novartis separately protects methods for treating nAMD with brolucizumab at intervals of ≥8 weeks, citing 95% visual stability rates with monthly ranibizumab in Phase 3 studies and framing extended intervals as the primary unmet need to be addressed. Kodiak Sciences (Koda Pharmaceutical) takes a different molecular approach: polymer-conjugated anti-VEGF antibodies (KSI-301) that extend IVT half-life, with subsequent dosing withheld until at least 20–24 weeks post-final loading dose — achieving interval extension through molecular engineering rather than dose escalation alone.

Delivery Route as an IP Battleground: Five Distinct Architectures

Delivery route has become a key IP dimension in the anti-VEGF retinal disease space, with active patent prosecution across at least five distinct approaches. Companies controlling both the therapeutic agent and the delivery device or formulation may gain durable IP advantages beyond molecule-level protection — a pattern recognised in innovation strategy literature tracked by organisations such as OECD in its assessments of biopharmaceutical IP ecosystems.

• Intravitreal (IVT) injection — the established standard, now being extended via dose escalation (Bayer, Novartis) and molecular engineering (Kodiak).
• Subretinal surgical delivery — used by RegenxBio for AAV vector delivery via pars plana vitrectomy under local anaesthesia. Retrieved filings describe dose cohorts of 3×10⁹, 1×10¹⁰, 6×10¹⁰, 16×10¹¹, and 25×10¹¹ genome copies — consistent with Phase 1/2 trial protocols.
• Suprachoroidal space (SCS) injection — RegenxBio has filed a cluster of 2023 patents on high-viscosity gel formulations and thermosensitive gelation (viscous/elastic at 32–35°C) for AAV vectors delivered to the SCS, designed to extend ocular clearance time and increase transduction dwell time. Clearside Biomedical separately protects microsyringe and microneedle devices for non-surgical SCS delivery of VEGF antagonists.
• Biodegradable implant injection — Vyluma Ocular Corporation and Vision Therapeutics protect biodegradable sustained-release implants containing axitinib (a tyrosine kinase inhibitor) dispersed in hydrogel matrices. Retrieved data indicate that axitinib polymorphic form IV suppresses VEGF-induced retinal vascular leakage for at least 3 months post-injection in rabbit models, with superior long-term efficacy compared to the less-soluble SAB-I form. Allergan (now AbbVie) separately describes biodegradable hyaluronic acid or PLGA polymer carriers for bevacizumab.
• Topical (eye drop) delivery — Ildong Pharmaceutical (South Korea) protects fusion proteins linking tissue-penetrating peptides to anti-VEGF agents, with the explicit aim of enabling topical delivery as an alternative to IVT injection. This approach also addresses drug resistance observed with approximately 70% of patients on standard anti-VEGF monotherapy, by improving choroidal penetration.

Emerging Targets, Combinations, and Precision Diagnostics Beyond the VEGF Axis

The anti-VEGF pipeline is diversifying beyond VEGF inhibition alone, with retrieved patent data from 2023–2025 signalling three distinct directions: novel co-targets, combination therapy protocols, and aqueous humor-based companion diagnostics for patient stratification.

PRL3: A Novel Co-Target for Refractory Disease

The Agency for Science, Technology and Research (Singapore) filed a 2025 WO patent identifying PRL3 (phosphatase of regenerating liver-3) as a biomarker elevated in neovascular eye disease and a target for combination with anti-VEGF agents. PRL3-binding antibodies are proposed as enhancers of anti-VEGF therapy efficacy, with PRL3 described as a mechanistically distinct co-target enabling patient stratification for combination therapy. The filing describes simultaneous or sequential co-administration — a signal of emerging mechanistic diversification beyond the VEGF axis that may redefine combination therapy protocols over the coming decade.

Anti-C5 Complement Combination

Ophthotech Corporation (now Iveric Bio) has filed on the combination of VEGF antagonists with anti-C5 agents (such as ARC1905/avacincaptad pegol), claiming synergistic efficacy above that of either agent alone in AMD-related conditions. This reflects a broader trend in ophthalmology toward targeting the complement cascade alongside VEGF — a direction also tracked by NIH-funded research into AMD pathogenesis.

Aqueous Humor VEGF as a Stratification Biomarker

Beijing SightNovo Medical Technology has patented methods to quantify aqueous humor VEGF levels using specific thresholds — less than 10 pg/mL versus greater than 100 pg/mL — to predict anatomical responsiveness to intravitreal, suprachoroidal, or subretinal VEGF antagonist treatment. This introduces a precision medicine stratification framework into the anti-VEGF paradigm: patients could be assigned to specific delivery routes based on their pre-treatment aqueous VEGF level, rather than receiving a uniform treatment protocol.

Long-Acting Protein Engineering: VEGFR-1 Heparin-Binding Fusion

The University of California Board of Regents describes engineering VEGFR-1 domain 2 — the critical VEGF and PlGF binding element — into Fc-IgG fusion proteins with strong heparin-binding capacity, intended to exploit heparin-binding VEGF isoforms for improved pharmacokinetics and extended vitreous half-life. This represents an alternative protein engineering approach to aflibercept, potentially offering lower dosing frequency without requiring dose escalation or viral vector delivery.

Strategic Implications for Drug Developers and IP Teams

The patent landscape for anti-VEGF therapy in neovascular retinal disease reveals a field undergoing simultaneous consolidation and diversification — with clear implications for IP strategy, clinical development, and competitive positioning.

Gene Therapy’s Durability Advantage Is Its Core Value Proposition

Retrieved Adverum data demonstrate resolution of IVT-refractory retinal fluid with a single rAAV dose at 6×10¹¹ vg/eye — directly addressing the chronic re-dosing burden that defines unmet need in nAMD. Adverum’s portfolio spans more than ten jurisdictions with a continuous filing window from 2017 to 2026, suggesting deep prosecution investment around a core AAV2 capsid variant-transgene combination. IP strategists should note that the refractory patient population — explicitly claimed in Adverum filings — may support accelerated regulatory pathways and represents a clinically validated indication with clear unmet need.

Delivery Route Control Creates Durable IP Moats

Companies controlling both the therapeutic agent and the delivery device or formulation — RegenxBio/SCS gel formulations, Clearside/SCS microsyringe devices, Vyluma/biodegradable axitinib implants — may gain IP advantages beyond molecule-level protection. With at least five distinct delivery routes actively prosecuted across this dataset, freedom-to-operate analysis must now encompass formulation and device claims, not just molecular composition claims. This multi-layer IP architecture is increasingly consistent with best practices documented by EPO in its technology landscape analyses of advanced therapy medicinal products.

The Assignee Landscape: Three Tiers of Activity

Patent activity in this dataset clusters into three tiers. Adverum Biotechnologies leads with the broadest multi-jurisdictional portfolio (WO, US, EP, AU, JP, SG, IN, MX, BR, CA, CN) and the longest continuous filing window (2017–2026). Bayer Healthcare and RegenxBio form a second tier, each with substantial multi-jurisdictional portfolios concentrated from 2020 onward. A third tier — Novartis, Clearside, University of California, Ildong, Kodiak, Beijing SightNovo, and Agency for Science, Technology and Research — each contributes single patent families representing specific molecular or delivery innovations. Academic-industrial partnerships (RegenxBio/Johns Hopkins) signal that university-originated IP may be a growing source of foundational claims in this space, consistent with innovation partnership models tracked by PatSnap’s life sciences intelligence platform.

Emerging Non-VEGF Targets Signal Pipeline Diversification

For academic researchers and investors, the PRL3 combination approach (2025, Agency for Science, Technology and Research) and VEGF-based aqueous humor biomarker stratification (Beijing SightNovo, 2023) represent early-stage innovation that could redefine patient selection and combination therapy protocols in neovascular retinal disease. These signals are currently underrepresented in the patent literature relative to the dominant VEGF-axis approaches — suggesting potential first-mover IP opportunities for teams willing to invest in these mechanistically distinct directions. Further analysis is available through PatSnap’s Insights blog and the PatSnap Eureka platform.